0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Glucagon Like Peptide 1 Agonist"

Following a topic allows Research and Markets to customize your experience and provide personalized recommendations.
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
From
EUR$600USDGBP
South America Diabetes Drug Market Outlook, 2030 - Product Thumbnail Image

South America Diabetes Drug Market Outlook, 2030

  • Report
  • June 2025
  • 81 Pages
From
EUR$3,450USDGBP
From
EUR$79USDGBP
EUR$156USDGBP
Loading Indicator

The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications. The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more

This website uses cookies to ensure you get the best experience. Learn more